Shield Therapeutics PLC's (LON:STX) Tim Watts caught up with Proactive London's Andrew Scott to recap on the big events of 2019 as well as to update on how US partnering discussions are coming along.
Shield ended the year with cash of £4.1mln, down from £9.8mln at the end of 2018. Following the receipt in January of the US$11.4mln upfront payment from ASK Pharm (its China partner), the group's cash runway now extends into 2021.
